Co-Founder & Chief Scientific Officer
Eric Gordon, PhD
Eric is a noted medicinal chemist and antibiotics expert. He has had a long career in biopharmaceuticals. He was a Director of medicinal chemistry at Squibb and Bristol-Myers Squibb, and was Vice President of Research at Affymax Research Institute as well as a Partner at Skyline Ventures for 11 years. He previously co-founded 2 previous anti-infective companies, Vicuron and Tetraphase. He is an accepted authority on combinatorial chemistry, medicinal chemistry, and creating drugs through enzyme inhibition. Eric has authored more than 200 scientific manuscripts and U.S. patents, and portions of 3 books, including editing a comprehensive book on combinatorial chemistry.
Co-Founder & Chief Executive Officer
John Freund, MD
John founded and runs Skyline Ventures, a well-known venture capital fund that invested in biopharmaceutical and medical device companies. He previously co-founded Intuitive Surgical, the leader in robotic surgery that is now a public company with a market capitalization of over $40 billion. Previously he was Executive Vice President of Acuson, a manufacturer of high-performance ultrasound imaging systems, and was a Co-Founder of the Healthcare Group in Corporate Finance at Morgan Stanley. He was Chairman of XenoPort whose focus was prodrug technology, a Director of Targanta, an antibiotic company that was sold to The Medicines Company in 2008, and is a Director of Tetraphase Pharmaceuticals, a public antibiotic company.
Co-founder & Consultant
Joaquim Trias, PhD
Joaquim is a microbiologist and an antibiotics expert. He has a had a long career in biopharmaceuticals, including being a Co-Founder of Peninsula Pharmaceuticals, Anthera and Tetraphase, with 2 approved anti-infectives and several drugs in phase 3. He was previously in leading positions at Versicor/Vicuron and Microcide Pharmaceuticals. He has extensively published on antibiotic resistance, and has multiple patents on antibiotic discovery.
Ronald W. Barrett, PhD
Ron was Co-Founder and CEO of XenoPort, a public biopharmaceutical company that developed prodrugs with increased clinical utility compared to the FDA-approved parent drug. Under his leadership, XenoPort advanced five prodrugs discovered in-house into human trials. These included Horizant® (gabapentin enacarbil) which is approved for two indications in the US, as well as three other drug candidates which are currently in clinical development. XenoPort was acquired by Arbor Pharmaceuticals in 2016. Prior to XenoPort, he was Senior Vice President of Research at Affymax Research Institute, a drug discovery company acquired by GlaxoSmithKline in 1995, and worked at Abbott Laboratories.